BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 12850996)

  • 21. Lessons learned from gene therapy concerning and the use of integrating vectors and the possible risk of insertional oncogenesis.
    Cichutek K
    Dev Biol (Basel); 2006; 123():29-34; discussion 55-73. PubMed ID: 16566434
    [No Abstract]   [Full Text] [Related]  

  • 22. Clinical research. Gene therapy a suspect in leukemia-like disease.
    Marshall E
    Science; 2002 Oct; 298(5591):34-5. PubMed ID: 12364755
    [No Abstract]   [Full Text] [Related]  

  • 23. A roadmap to safe, efficient, and stable lentivirus-mediated gene therapy with hematopoietic cell transplantation.
    Neschadim A; McCart JA; Keating A; Medin JA
    Biol Blood Marrow Transplant; 2007 Dec; 13(12):1407-16. PubMed ID: 18022569
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bubble babies and bathwater.
    Nat Biotechnol; 2002 Nov; 20(11):1063. PubMed ID: 12410236
    [No Abstract]   [Full Text] [Related]  

  • 25. Activation of the T-cell oncogene LMO2 after gene therapy for X-linked severe combined immunodeficiency.
    McCormack MP; Rabbitts TH
    N Engl J Med; 2004 Feb; 350(9):913-22. PubMed ID: 14985489
    [No Abstract]   [Full Text] [Related]  

  • 26. Safety and efficacy in retrovirally modified haematopoietic cell therapy.
    Li Z; Modlich U; Baum C
    Best Pract Res Clin Haematol; 2004 Sep; 17(3):493-503. PubMed ID: 15498719
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Hematopoietic malignancies and gene therapy].
    Ozawa K
    Gan To Kagaku Ryoho; 2003 Apr; 30(4):478-82. PubMed ID: 12722677
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Retroviral vector integration deregulates gene expression but has no consequence on the biology and function of transplanted T cells.
    Recchia A; Bonini C; Magnani Z; Urbinati F; Sartori D; Muraro S; Tagliafico E; Bondanza A; Stanghellini MT; Bernardi M; Pescarollo A; Ciceri F; Bordignon C; Mavilio F
    Proc Natl Acad Sci U S A; 2006 Jan; 103(5):1457-62. PubMed ID: 16432223
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Retroviral vectors: new applications for an old tool.
    Barquinero J; Eixarch H; Pérez-Melgosa M
    Gene Ther; 2004 Oct; 11 Suppl 1():S3-9. PubMed ID: 15454951
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Regulators split on gene therapy as patient shows signs of cancer.
    Check E
    Nature; 2002 Oct; 419(6907):545-6. PubMed ID: 12374936
    [No Abstract]   [Full Text] [Related]  

  • 31. Gene therapy. RAC hears a plea for resuming trials, despite cancer risk.
    Kaiser J
    Science; 2003 Feb; 299(5609):991. PubMed ID: 12586909
    [No Abstract]   [Full Text] [Related]  

  • 32. Gene therapy. RAC's advice: proceed with caution.
    Kaiser J
    Science; 2002 Dec; 298(5601):2113-5. PubMed ID: 12481114
    [No Abstract]   [Full Text] [Related]  

  • 33. Murine leukemia induced by retroviral gene marking.
    Li Z; Düllmann J; Schiedlmeier B; Schmidt M; von Kalle C; Meyer J; Forster M; Stocking C; Wahlers A; Frank O; Ostertag W; Kühlcke K; Eckert HG; Fehse B; Baum C
    Science; 2002 Apr; 296(5567):497. PubMed ID: 11964471
    [No Abstract]   [Full Text] [Related]  

  • 34. Successful reconstitution of immunity in ADA-SCID by stem cell gene therapy following cessation of PEG-ADA and use of mild preconditioning.
    Gaspar HB; Bjorkegren E; Parsley K; Gilmour KC; King D; Sinclair J; Zhang F; Giannakopoulos A; Adams S; Fairbanks LD; Gaspar J; Henderson L; Xu-Bayford JH; Davies EG; Veys PA; Kinnon C; Thrasher AJ
    Mol Ther; 2006 Oct; 14(4):505-13. PubMed ID: 16905365
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fragile sites are preferential targets for integrations of MLV vectors in gene therapy.
    Bester AC; Schwartz M; Schmidt M; Garrigue A; Hacein-Bey-Abina S; Cavazzana-Calvo M; Ben-Porat N; Von Kalle C; Fischer A; Kerem B
    Gene Ther; 2006 Jul; 13(13):1057-9. PubMed ID: 16511518
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genes can come true.
    Phillips H
    New Sci; 2002 Nov; 176(2371):30-3. PubMed ID: 12731520
    [No Abstract]   [Full Text] [Related]  

  • 37. Gene therapy. Seeking the cause of induced leukemias in X-SCID trial.
    Kaiser J
    Science; 2003 Jan; 299(5606):495. PubMed ID: 12543948
    [No Abstract]   [Full Text] [Related]  

  • 38. [Gene therapy of severe combined immunodeficiency disease: proof of principle of efficiency and safety issues. Gene therapy, primary immunodeficiencies, retrovirus, lentivirus, genome].
    Fischer A; Hacein-Bey-Abina S; Lagresle C; Garrigue A; Cavazana-Calvo M
    Bull Acad Natl Med; 2005 May; 189(5):779-85; discussion 786-8. PubMed ID: 16433450
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficiency of transduction of highly purified murine hematopoietic stem cells by lentiviral and oncoretroviral vectors under conditions of minimal in vitro manipulation.
    Mostoslavsky G; Kotton DN; Fabian AJ; Gray JT; Lee JS; Mulligan RC
    Mol Ther; 2005 Jun; 11(6):932-40. PubMed ID: 15922964
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Of mice and men: the tale of two therapies.
    Hawley RG; Sobieski DA
    Stem Cells; 2002; 20(4):275-8. PubMed ID: 12110695
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.